Frelii, Inc. (OTC: FRLI) Developing personalized medicine using DNA big data & AI



Ian Jenkins, CEO








Frelii, Inc. (OTC: FRLI), interview with CEO Ian Jenkins discussing the company’s personalized medicine technology which uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome.

 Ian explains how Frelii is starting to commercialize it’s technology with initial applications in medical cannabis, and psychotropic medicines. 



Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.